REGN Jan 2025 830.000 call
| Previous close | 135.02 |
| Open | 135.02 |
| Bid | 181.00 |
| Ask | 188.40 |
| Strike | 830.00 |
| Expiry date | 2025-01-17 |
| Day's range | 135.02 - 135.02 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
- Thomson Reuters StreetEvents
Q1 2024 Intellia Therapeutics Inc Earnings Call
Q1 2024 Intellia Therapeutics Inc Earnings Call
GlobeNewswireLatest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi
- GlobeNewswire
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website
